非ホジキンリンパ腫治療市場：治療タイプ、用途、エンドユーザー別-2024年～2030年の世界予測

非ホジキンリンパ腫治療市場規模は2023年に82億米ドルと推計され、2024年には88億4,000万米ドルに達し、CAGR 7.91％で2030年には139億8,000万米ドルに達すると予測されます。

非ホジキンリンパ腫は、胃や腸などの臓器にあるリンパ節やリンパ組織で始まり発症するがんの一種です。首のリンパ節の腫れ、腹痛や腫れ、胸の痛み、咳、呼吸困難などがこの病気の一般的な症状です。非ホジキンリンパ腫（NHL）の治療法には、化学療法、放射線療法、プラズマフェレーシス標的療法、幹細胞移植などがあります。非ホジキンリンパ腫の新しい治療法は、がん細胞を特異的に攻撃するように設計された個別化薬、標的薬、免疫療法の開発に重点を置いています。ライフスタイルの変化や肥満の増加は、がんや腫瘍に苦しむ患者の急増につながっています。さらに、有望な薬剤の上市やリンパ腫に対する薬剤の承認数が急速に増加しています。しかし、がん治療オプションの利用には高額な費用がかかるため、治療オプションへのアクセシビリティが低下しています。さらに、がん治療オプションに対する厳しい規制が、研究機関のがん治療研究への投資を抑制し、新薬の商業化を妨げています。がんやその治療法に関する認識を高めることに政府が注力していることは、複雑な規制がもたらす障壁の数を減らす一助となり得る。バイオテクノロジーや製薬機関・企業は、抗体薬物複合体やプロテアソーム阻害剤など、がんを標的とした生物学的療法や薬剤の選択肢を導入しています。

治療の種類体の他の部分へのがんの転移を防ぐ化学療法治療

化学療法は、がん細胞の分裂と増殖を阻止し、がんの進行を防ぐ。化学療法は、静脈に直接点滴する方法（静脈内化学療法）、錠剤として投与する方法、またはその両方を組み合わせて投与する方法があります。また、化学療法薬の中には、筋肉や関節の痛み、頭痛、胃痛など、痛みを伴う副作用を引き起こすものもあります。免疫療法もがん治療の一種で、がん細胞を破壊するために患者の体の免疫システムを利用し、モノクローナル抗体やバイスペシフィック抗体という抗体を用いてがん細胞を標的にします。放射線療法は、がん細胞を死滅させるために強力なエネルギー線（多くはX線）を使用します。外部放射線療法は、非ホジキンリンパ腫に対して最も一般的に用いられる治療法です。幹細胞移植は、がん化し損傷した幹細胞を健康な幹細胞と置き換えるために用いられる治療法です。標的療法とは、特定のがん細胞を特異的に識別して攻撃するために化学薬剤を利用するがん治療を指します。標的療法は、それ自体として、あるいは従来の標準的な化学療法や放射線療法などの他の治療法と組み合わせて、治療の選択肢として使用することができます。

応用例びまん性大細胞型B細胞リンパ腫（DLBCL）の進行期治療における免疫療法と放射線療法の併用

びまん性大細胞型B細胞リンパ腫（DLBCL）は非ホジキンリンパ腫（NHL）の一種で、患者の体内で異常なBリンパ球が作られ、急速に増殖することで発症します。治療戦略としては、薬剤を併用した化学療法やモノクローナル抗体による治療が行われます。濾胞性リンパ腫は、低悪性度の非ホジキンリンパ腫（NHL）の一種で、リンパ腺や臓器に白血球が集まって発生します。放射線療法、免疫化学療法、免疫療法が一般的な治療法です。マントル細胞リンパ腫（MCL）は、非ホジキンリンパ腫（NHL）の中でも侵攻性でまれな病型であり、リンパ節のマントル帯を侵します。このようながんの治療には、しばしば化学療法薬と免疫療法が用いられます。

エンドユーザー病院における非ホジキンリンパ腫治療の新規戦略の採用増加

病院は非ホジキンリンパ腫の治療に免疫療法や化学療法を急速に導入しています。また、病院に一泊する必要のない新しい治療法の開発にも投資しています。がんセンターとは、最新の研究活動から生み出された科学的知識を、がん患者のための有望な実験室での治療法へと発展させ、翻訳する機関を指します。在宅ケアサービスは、患者が自宅で治療やケアを受けられるようにするもので、特に高齢の患者や特別なニーズのある患者に有利です。在宅介護サービスには、患者の回復のための様々な医療、社会、リハビリテーションサービスが含まれます。

地域別洞察

米国やカナダのような南北南北アメリカの主要国は、がん治療に対する治療選択肢や償還制度に対する認識が高いです。非ホジキンリンパ腫治療の南北アメリカ市場は、同地域のがん治療センターとがん専門医の増加によって牽引されています。さらに、南北アメリカ諸国には大手バイオテクノロジー企業や製薬企業が存在し、非ホジキンリンパ腫の治療ソリューションが数多く導入されていることが特徴です。中国を含むアジア諸国は、がん治療薬の承認数を増やすことに重点を置いています。各国政府は、リンパ腫とその症状に対する認識を向上させるために急速に努力を注いでいます。欧州諸国には、非ホジキンリンパ腫やその他のがんに関する研究開発活動に積極的に関与する学術研究機関が確立されています。さらに、バイオテクノロジー企業と政府間の臨床試験や共同研究の増加が、新規治療法の導入に向けた重要な促進要因となっています。

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスは非ホジキンリンパ腫治療市場を評価する上で極めて重要です。事業戦略と製品満足度に関連する主要指標を調査し、ベンダーの包括的な評価を提供します。この綿密な分析により、ユーザーは各自の要件に沿った十分な情報に基づいた意思決定を行うことができます。評価に基づき、ベンダーは成功の度合いが異なる4つの象限に分類されます：フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。

市場シェア分析

市場シェア分析は、非ホジキンリンパ腫治療市場におけるベンダーの現状について、洞察に満ちた詳細な調査を提供する包括的なツールです。全体的な収益、顧客基盤、その他の主要指標についてベンダーの貢献度を綿密に比較・分析することで、企業の業績や市場シェア争いの際に直面する課題について理解を深めることができます。さらに、この分析により、調査対象基準年に観察された累積、断片化の優位性、合併の特徴などの要因を含む、この分野の競合特性に関する貴重な考察が得られます。このような詳細レベルの拡大により、ベンダーはより多くの情報に基づいた意思決定を行い、市場で競争優位に立つための効果的な戦略を考案することができます。

本レポートは、以下の側面に関する貴重な洞察を提供しています：

1.市場の浸透度：主要企業が提供する市場に関する包括的な情報を提示しています。

2.市場の開拓度：有利な新興市場を深く掘り下げ、成熟市場セグメントにおける浸透度を分析しています。

3.市場の多様化：新製品の発売、未開拓の地域、最近の開発、投資に関する詳細な情報を提供します。

4.競合の評価と情報：市場シェア、戦略、製品、認証、規制状況、特許状況、主要企業の製造能力について徹底的な評価を行います。

5.製品開発およびイノベーション：将来の技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような主要な質問に対応しています：

1.非ホジキンリンパ腫治療市場の市場規模および予測は？

2.非ホジキンリンパ腫治療市場の予測期間中に投資を検討すべき製品、セグメント、用途、分野は何か？

3.非ホジキンリンパ腫治療市場の技術動向と規制枠組みは？

4.非ホジキンリンパ腫治療市場における主要ベンダーの市場シェアは？

5.非ホジキンリンパ腫治療市場への参入に適した形態や戦略的手段は？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 非ホジキンリンパ腫の罹患率の上昇
    • リンパ腫に対する有望な薬の発売と薬の承認
    • 第一線の治療計画におけるNHL患者の予後と標準治療の重視
  • 抑制要因
    • 治療費が高く、副作用もある
  • 機会
    • 病気に対する治療薬の研究開発の増加
    • 政府や非営利団体からの投資増加
  • 課題
    • がん治療の選択肢に対する厳しい規制
• 市場セグメンテーション分析
  • 治療の種類：がんが体の他の部位に転移するのを防ぐための化学療法
  • 応用：びまん性大細胞型B細胞リンパ腫（DLBCL）の進行期治療における免疫療法と放射線の利用
  • エンドユーザー：病院におけるNHL治療のための新しい戦略の採用の増加
• 市場ディスラプション分析
• ポーターのファイブフォース分析
• バリューチェーンとクリティカルパス分析
• 価格分析
• 技術分析
• 特許分析
• 貿易分析
• 規制枠組みの分析

第6章 非ホジキンリンパ腫治療市場：治療タイプ別

• 化学療法
• 免疫療法
• 放射線治療
• 幹細胞移植
• 標的療法

第7章 非ホジキンリンパ腫治療市場：用途別

• びまん性大細胞型B細胞リンパ腫
• 濾胞性リンパ腫
• マントル細胞リンパ腫

第8章 非ホジキンリンパ腫治療市場：エンドユーザー別

• がんセンター
• ホームケア
• 病院

第9章 南北アメリカの非ホジキンリンパ腫治療市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋の非ホジキンリンパ腫治療市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカの非ホジキンリンパ腫治療市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析、2023年
• FPNVポジショニングマトリックス、2023年
• 競合シナリオ分析
  • EPKINLY（エプコリタマブ-bysp）が、再発性または難治性のびまん性大細胞型B細胞リンパ腫（DLBCL）の成人患者を治療する初の、そして唯一の二重特異性抗体として米国FDAの承認を取得
  • ヤンセン、次世代CAR-T療法の開発に向けセルラーバイオメディシングループと世界規模の提携およびライセンス契約を締結
  • バイオジェン、抗CD20コラボレーションの一環として後期段階の二重特異性抗体の商業化の可能性に対するロイヤルティを受け取ることでジェネンテックと合意
• 戦略分析と提言

第13章 競合ポートフォリオ

• 主要企業プロファイル
• 主要製品ポートフォリオ

LIST OF FIGURES

• FIGURE 1. NON-HODGKIN LYMPHOMA TREATMENT MARKET RESEARCH PROCESS
• FIGURE 2. NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY REGION, 2023 VS 2030 (%)
• FIGURE 5. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. NON-HODGKIN LYMPHOMA TREATMENT MARKET DYNAMICS
• FIGURE 7. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2030 (%)
• FIGURE 8. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 9. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
• FIGURE 10. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 11. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
• FIGURE 12. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 13. AMERICAS NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 14. AMERICAS NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 15. UNITED STATES NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 16. UNITED STATES NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 17. ASIA-PACIFIC NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 18. ASIA-PACIFIC NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 20. EUROPE, MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 21. NON-HODGKIN LYMPHOMA TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 22. NON-HODGKIN LYMPHOMA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. NON-HODGKIN LYMPHOMA TREATMENT MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2023 (USD MILLION)
• TABLE 4. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2024-2030 (USD MILLION)
• TABLE 5. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
• TABLE 6. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
• TABLE 7. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
• TABLE 8. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
• TABLE 9. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2023 (USD MILLION)
• TABLE 10. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2024-2030 (USD MILLION)
• TABLE 11. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2023 (USD MILLION)
• TABLE 12. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2024-2030 (USD MILLION)
• TABLE 13. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY RADIATION THERAPY, BY REGION, 2018-2023 (USD MILLION)
• TABLE 14. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY RADIATION THERAPY, BY REGION, 2024-2030 (USD MILLION)
• TABLE 15. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY STEM CELL TRANSPLANTATION, BY REGION, 2018-2023 (USD MILLION)
• TABLE 16. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY STEM CELL TRANSPLANTATION, BY REGION, 2024-2030 (USD MILLION)
• TABLE 17. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2023 (USD MILLION)
• TABLE 18. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2024-2030 (USD MILLION)
• TABLE 19. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 20. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 21. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY DIFFUSE LARGE B-CELL LYMPHOMA, BY REGION, 2018-2023 (USD MILLION)
• TABLE 22. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY DIFFUSE LARGE B-CELL LYMPHOMA, BY REGION, 2024-2030 (USD MILLION)
• TABLE 23. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY FOLLICULAR LYMPHOMA, BY REGION, 2018-2023 (USD MILLION)
• TABLE 24. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY FOLLICULAR LYMPHOMA, BY REGION, 2024-2030 (USD MILLION)
• TABLE 25. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY MANTLE CELL LYMPHOMA, BY REGION, 2018-2023 (USD MILLION)
• TABLE 26. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY MANTLE CELL LYMPHOMA, BY REGION, 2024-2030 (USD MILLION)
• TABLE 27. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 28. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 29. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CANCER CENTERS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 30. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CANCER CENTERS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 31. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY HOME CARE, BY REGION, 2018-2023 (USD MILLION)
• TABLE 32. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY HOME CARE, BY REGION, 2024-2030 (USD MILLION)
• TABLE 33. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 34. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 35. AMERICAS NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
• TABLE 36. AMERICAS NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
• TABLE 37. AMERICAS NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 38. AMERICAS NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 39. AMERICAS NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 40. AMERICAS NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 41. AMERICAS NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 42. AMERICAS NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 43. ARGENTINA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
• TABLE 44. ARGENTINA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
• TABLE 45. ARGENTINA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 46. ARGENTINA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 47. ARGENTINA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 48. ARGENTINA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 49. BRAZIL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
• TABLE 50. BRAZIL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
• TABLE 51. BRAZIL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 52. BRAZIL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 53. BRAZIL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 54. BRAZIL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 55. CANADA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
• TABLE 56. CANADA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
• TABLE 57. CANADA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 58. CANADA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 59. CANADA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 60. CANADA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 61. MEXICO NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
• TABLE 62. MEXICO NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
• TABLE 63. MEXICO NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 64. MEXICO NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 65. MEXICO NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 66. MEXICO NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 67. UNITED STATES NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
• TABLE 68. UNITED STATES NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
• TABLE 69. UNITED STATES NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 70. UNITED STATES NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 71. UNITED STATES NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 72. UNITED STATES NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 73. UNITED STATES NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
• TABLE 74. UNITED STATES NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
• TABLE 75. ASIA-PACIFIC NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
• TABLE 76. ASIA-PACIFIC NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
• TABLE 77. ASIA-PACIFIC NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 78. ASIA-PACIFIC NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 79. ASIA-PACIFIC NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 80. ASIA-PACIFIC NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 81. ASIA-PACIFIC NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 82. ASIA-PACIFIC NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 83. AUSTRALIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
• TABLE 84. AUSTRALIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
• TABLE 85. AUSTRALIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 86. AUSTRALIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 87. AUSTRALIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 88. AUSTRALIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 89. CHINA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
• TABLE 90. CHINA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
• TABLE 91. CHINA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 92. CHINA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 93. CHINA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 94. CHINA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 95. INDIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
• TABLE 96. INDIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
• TABLE 97. INDIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 98. INDIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 99. INDIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 100. INDIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 101. INDONESIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
• TABLE 102. INDONESIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
• TABLE 103. INDONESIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 104. INDONESIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 105. INDONESIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 106. INDONESIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 107. JAPAN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
• TABLE 108. JAPAN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
• TABLE 109. JAPAN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 110. JAPAN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 111. JAPAN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 112. JAPAN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 113. MALAYSIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
• TABLE 114. MALAYSIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
• TABLE 115. MALAYSIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 116. MALAYSIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 117. MALAYSIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 118. MALAYSIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 119. PHILIPPINES NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
• TABLE 120. PHILIPPINES NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
• TABLE 121. PHILIPPINES NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 122. PHILIPPINES NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 123. PHILIPPINES NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 124. PHILIPPINES NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 125. SINGAPORE NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
• TABLE 126. SINGAPORE NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
• TABLE 127. SINGAPORE NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 128. SINGAPORE NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 129. SINGAPORE NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 130. SINGAPORE NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 131. SOUTH KOREA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
• TABLE 132. SOUTH KOREA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
• TABLE 133. SOUTH KOREA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 134. SOUTH KOREA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 135. SOUTH KOREA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 136. SOUTH KOREA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 137. TAIWAN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
• TABLE 138. TAIWAN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
• TABLE 139. TAIWAN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 140. TAIWAN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 141. TAIWAN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 142. TAIWAN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 143. THAILAND NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
• TABLE 144. THAILAND NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
• TABLE 145. THAILAND NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 146. THAILAND NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 147. THAILAND NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 148. THAILAND NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 149. VIETNAM NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
• TABLE 150. VIETNAM NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
• TABLE 151. VIETNAM NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 152. VIETNAM NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 153. VIETNAM NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 154. VIETNAM NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 155. EUROPE, MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
• TABLE 156. EUROPE, MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
• TABLE 157. EUROPE, MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 158. EUROPE, MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 159. EUROPE, MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 160. EUROPE, MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 161. EUROPE, MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 162. EUROPE, MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 163. DENMARK NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
• TABLE 164. DENMARK NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
• TABLE 165. DENMARK NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 166. DENMARK NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 167. DENMARK NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 168. DENMARK NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 169. EGYPT NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
• TABLE 170. EGYPT NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
• TABLE 171. EGYPT NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 172. EGYPT NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 173. EGYPT NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 174. EGYPT NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 175. FINLAND NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
• TABLE 176. FINLAND NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
• TABLE 177. FINLAND NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 178. FINLAND NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 179. FINLAND NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 180. FINLAND NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 181. FRANCE NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
• TABLE 182. FRANCE NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
• TABLE 183. FRANCE NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 184. FRANCE NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 185. FRANCE NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 186. FRANCE NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 187. GERMANY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
• TABLE 188. GERMANY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
• TABLE 189. GERMANY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 190. GERMANY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 191. GERMANY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 192. GERMANY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 193. ISRAEL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
• TABLE 194. ISRAEL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
• TABLE 195. ISRAEL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 196. ISRAEL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 197. ISRAEL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 198. ISRAEL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 199. ITALY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
• TABLE 200. ITALY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
• TABLE 201. ITALY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 202. ITALY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 203. ITALY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 204. ITALY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 205. NETHERLANDS NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
• TABLE 206. NETHERLANDS NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
• TABLE 207. NETHERLANDS NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 208. NETHERLANDS NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 209. NETHERLANDS NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 210. NETHERLANDS NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 211. NIGERIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
• TABLE 212. NIGERIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
• TABLE 213. NIGERIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 214. NIGERIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 215. NIGERIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 216. NIGERIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 217. NORWAY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
• TABLE 218. NORWAY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
• TABLE 219. NORWAY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 220. NORWAY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 221. NORWAY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 222. NORWAY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 223. POLAND NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
• TABLE 224. POLAND NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
• TABLE 225. POLAND NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 226. POLAND NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 227. POLAND NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 228. POLAND NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 229. QATAR NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
• TABLE 230. QATAR NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
• TABLE 231. QATAR NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 232. QATAR NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 233. QATAR NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 234. QATAR NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 235. RUSSIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
• TABLE 236. RUSSIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
• TABLE 237. RUSSIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 238. RUSSIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 239. RUSSIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 240. RUSSIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 241. SAUDI ARABIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
• TABLE 242. SAUDI ARABIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
• TABLE 243. SAUDI ARABIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 244. SAUDI ARABIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 245. SAUDI ARABIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 246. SAUDI ARABIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 247. SOUTH AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
• TABLE 248. SOUTH AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
• TABLE 249. SOUTH AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 250. SOUTH AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 251. SOUTH AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 252. SOUTH AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 253. SPAIN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
• TABLE 254. SPAIN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
• TABLE 255. SPAIN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 256. SPAIN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 257. SPAIN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 258. SPAIN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 259. SWEDEN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
• TABLE 260. SWEDEN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
• TABLE 261. SWEDEN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 262. SWEDEN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 263. SWEDEN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 264. SWEDEN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 265. SWITZERLAND NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
• TABLE 266. SWITZERLAND NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
• TABLE 267. SWITZERLAND NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 268. SWITZERLAND NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 269. SWITZERLAND NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 270. SWITZERLAND NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 271. TURKEY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
• TABLE 272. TURKEY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
• TABLE 273. TURKEY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 274. TURKEY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 275. TURKEY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 276. TURKEY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 277. UNITED ARAB EMIRATES NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
• TABLE 278. UNITED ARAB EMIRATES NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
• TABLE 279. UNITED ARAB EMIRATES NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 280. UNITED ARAB EMIRATES NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 281. UNITED ARAB EMIRATES NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 282. UNITED ARAB EMIRATES NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 283. UNITED KINGDOM NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
• TABLE 284. UNITED KINGDOM NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
• TABLE 285. UNITED KINGDOM NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 286. UNITED KINGDOM NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 287. UNITED KINGDOM NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 288. UNITED KINGDOM NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 289. NON-HODGKIN LYMPHOMA TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 290. NON-HODGKIN LYMPHOMA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

[185 Pages Report] The Non-Hodgkin Lymphoma Treatment Market size was estimated at USD 8.20 billion in 2023 and expected to reach USD 8.84 billion in 2024, at a CAGR 7.91% to reach USD 13.98 billion by 2030.

Non-Hodgkin Lymphoma refers to a type of cancer that begins and develops in the lymph nodes and lymphatic tissue found in organs, including the stomach and intestines. Swollen lymph nodes in the neck, abdominal pain or swelling, chest pain, coughing, or trouble breathing are some common symptoms of the disease. Treatment options for non-Hodgkin lymphoma (NHL) include chemotherapy, radiation, plasmapheresis targeted therapy, and stem cell transplant. Newer treatment options for non-Hodgkin lymphoma are focused on making personalized medications, targeted drugs, and immunotherapy engineered to attack cancer cells specifically. Changing lifestyles and rising incidences of obesity have led to a surge in the number of patients suffering from cancers and tumors. Additionally, the launch of promising drugs and the number of drug approvals for lymphomas is rapidly increasing. However, the high cost of availing cancer treatment options reduces the accessibility of treatment options. Furthermore, stringent regulations for cancer treatment options have dissuaded research institutions from investing in cancer treatment research and have hampered the commercialization of novel drugs. The government's focus on increasing awareness about cancer and its treatment options is gaining traction and can aid in reducing the number of barriers posed by complex regulations. Biotechnology, and pharmaceutical institutions and companies have introduced targeted biological therapies and drug options for cancer, such as antibody-drug conjugate and proteasome inhibitors.

Treatment type: Chemotherapy treatments to prevent the spread of cancer to other parts of the body

Chemotherapy prevents the division and growth of cancer cells, thereby preventing the progression of cancers. It is provided through a drip directly into the vein (intravenous chemotherapy), as tablets or a combination of both. Besides, some chemotherapy drugs can cause painful side effects, such as aching in the muscles and joints, headaches and stomach pains. Immunotherapy is another type of cancer treatment that uses the patient's body's immune system to destroy cancer cells and uses antibodies, monoclonal or bispecific antibodies, to target cancer cells. Radiation therapy uses rays of intense energy, often X-rays, to kill cancer cells. External radiation therapy is the most commonly used treatment strategy for NHL). Stem cell transplants are procedures that are used to replace cancerous, damaged stem cells with healthy ones. Targeted therapy refers to cancer treatment that utilizes chemical drugs to specifically identify and attack certain cancer cells. Targeted therapy can be used as a treatment option in itself or in combination with other treatments, such as traditional or standard chemotherapy or radiation therapy.

Application: Utilization of immunotherapy and radiation in advanced stages treatment of diffuse large B cell lymphoma (DLBCL)

Diffuse large B cell lymphoma (DLBCL) refers to a type of non-Hodgkin lymphoma (NHL) that starts developing when the patient's body makes abnormal B lymphocytes and proliferates quickly. The treatment strategies used include chemotherapy in combination with drugs or treatment with plus monoclonal antibodies. Follicular lymphoma refers to a type of low-grade non-Hodgkin lymphoma (NHL) that is formed due to the clustering of white blood cells in the lymph glands or organs. Radiation, immunochemotherapy, and immunotherapy are commonly used treatment options. Mantle Cell lymphoma (MCL) is an aggressive, rare form of non-Hodgkin lymphoma (NHL) that affects the mantle zone of the lymph node. Often, chemotherapy drugs and immunotherapy are used to treat such cancers.

End-user: Increasing adoption of novel strategies for NHL treatment in hospitals

Hospitals are rapidly adopting immunotherapies and chemotherapies for the treatment of NHL. They are also investing in the development of novel therapies that don't require an overnight stay in hospitals. Cancer centers refer to institutions that develop and translate scientific knowledge generated from the latest research activities into promising laboratory treatments for cancer patients. Home care services allow a patient to acquire treatment and care from their own homes and is specifically advantageous for elderly patients and patients with special needs. Home care services involve a range of health, social, and rehabilitative services for the recovery of patients.

Regional Insights

Significant Americas countries, such as the USA and Canada, are associated with a higher awareness of the availability of treatment options and reimbursement plans for cancer treatment. The Americas market for NHL treatment is driven by the increasing number of cancer care centers and oncology specialists in the region. Additionally, Americas countries are characterized by the presence of major biotechnology and pharmaceutical companies and a large number of treatment solutions introduced for Non hodgkin lymphoma. Countries in Asia, including China, have expanded their focus on increasing the number of drug approvals for cancer treatment. Governments are rapidly investing their efforts to improve awareness of lymphomas and their symptoms. European nations have well-established academic and research institutions that are actively involved in research and development activities concerning non-Hodgkin lymphoma and other cancers. Additionally, the growing number of clinical trials and collaborations between biotechnology companies and governments has been a significant driving factor towards the introduction of novel treatment therapies.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Non-Hodgkin Lymphoma Treatment Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Non-Hodgkin Lymphoma Treatment Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Non-Hodgkin Lymphoma Treatment Market, highlighting leading vendors and their innovative profiles. These include AstraZeneca PLC, Aurobindo Pharma, Bayer AG, Cipla Inc., Dr. Reddy's Laboratories Ltd., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Gilead Sciences, Inc., GlaxoSmithKline PLC, Hetero Drugs Ltd., Hikma Pharmaceuticals PLC, Intas Pharmaceuticals Ltd., Janssen Global Services, LLC, Kyowa Kirin Co., Ltd., Lupin Ltd., Merck KGaA, Nordic Nanovector ASA by Thor Medical, Novartis AG, Pharmacyclics, LLC, Salvavidas Pharmaceutical Pvt. Ltd., Sanofi S.A., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., and Zydus Pharmaceuticals.

Market Segmentation & Coverage

This research report categorizes the Non-Hodgkin Lymphoma Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Treatment Type
  • Chemotherapy
  • Immunotherapy
  • Radiation Therapy
  • Stem Cell Transplantation
  • Targeted Therapy

• Application
  • Diffuse Large B-cell Lymphoma
  • Follicular Lymphoma
  • Mantle Cell Lymphoma

• End-User
  • Cancer Centers
  • Home Care
  • Hospitals

• Region
  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam

• Europe, Middle East & Africa
  • Denmark
  • Egypt
  • Finland
  • France
  • Germany
  • Israel
  • Italy
  • Netherlands
  • Nigeria
  • Norway
  • Poland
  • Qatar
  • Russia
  • Saudi Arabia
  • South Africa
  • Spain
  • Sweden
  • Switzerland
  • Turkey
  • United Arab Emirates
  • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Non-Hodgkin Lymphoma Treatment Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Non-Hodgkin Lymphoma Treatment Market?

3. What are the technology trends and regulatory frameworks in the Non-Hodgkin Lymphoma Treatment Market?

4. What is the market share of the leading vendors in the Non-Hodgkin Lymphoma Treatment Market?

5. Which modes and strategic moves are suitable for entering the Non-Hodgkin Lymphoma Treatment Market?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising prevalence of non-Hodgkin lymphoma disease
    • 5.1.1.2. The launch of promising drugs and drug approval for lymphomas
    • 5.1.1.3. Emphasis on NHL patient prognosis and standard of care in front-line treatment regimens
  • 5.1.2. Restraints
    • 5.1.2.1. High cost of the treatment and certain side effects
  • 5.1.3. Opportunities
    • 5.1.3.1. Increase in research and development of therapeutic drugs against the disease
    • 5.1.3.2. Rising investments from government and non-profit organizations
  • 5.1.4. Challenges
    • 5.1.4.1. Stringent regulations for cancer treatment options
• 5.2. Market Segmentation Analysis
  • 5.2.1. Treatment type: Chemotherapy treatments to prevent the spread of cancer to other parts of the body
  • 5.2.2. Application: Utilization of immunotherapy and radiation in advanced stages treatment of diffuse large B cell lymphoma (DLBCL)
  • 5.2.3. End-user: Increasing adoption of novel strategies for NHL treatment in hospitals
• 5.3. Market Disruption Analysis
• 5.4. Porter's Five Forces Analysis
  • 5.4.1. Threat of New Entrants
  • 5.4.2. Threat of Substitutes
  • 5.4.3. Bargaining Power of Customers
  • 5.4.4. Bargaining Power of Suppliers
  • 5.4.5. Industry Rivalry
• 5.5. Value Chain & Critical Path Analysis
• 5.6. Pricing Analysis
• 5.7. Technology Analysis
• 5.8. Patent Analysis
• 5.9. Trade Analysis
• 5.10. Regulatory Framework Analysis

6. Non-Hodgkin Lymphoma Treatment Market, by Treatment Type

• 6.1. Introduction
• 6.2. Chemotherapy
• 6.3. Immunotherapy
• 6.4. Radiation Therapy
• 6.5. Stem Cell Transplantation
• 6.6. Targeted Therapy

7. Non-Hodgkin Lymphoma Treatment Market, by Application

• 7.1. Introduction
• 7.2. Diffuse Large B-cell Lymphoma
• 7.3. Follicular Lymphoma
• 7.4. Mantle Cell Lymphoma

8. Non-Hodgkin Lymphoma Treatment Market, by End-User

• 8.1. Introduction
• 8.2. Cancer Centers
• 8.3. Home Care
• 8.4. Hospitals

9. Americas Non-Hodgkin Lymphoma Treatment Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Non-Hodgkin Lymphoma Treatment Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Non-Hodgkin Lymphoma Treatment Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
  • 12.3.1. EPKINLY (epcoritamab-bysp) Approved by U.S. FDA as the First and Only Bispecific Antibody to Treat Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
  • 12.3.2. Janssen Enters Worldwide Collaboration and License Agreement with Cellular Biomedicine Group to Develop Next Generation CAR-T Therapies
  • 12.3.3. Biogen Reaches Agreement with Genentech to Receive Royalties on the Potential Commercialization of a Late-Stage Bispecific Antibody as Part of Anti-CD20 Collaboration
• 12.4. Strategy Analysis & Recommendation

13. Competitive Portfolio

• 13.1. Key Company Profiles
• 13.2. Key Product Portfolio